Botulinum Toxin InjectionFEMFALLTOXNCT07108920
Analysis of Balance Disorders After Botulinum Toxin Treatment in the Rectus Femoris in Patients With a Stiff Knee Gait
An observational study of Botulinum Toxin Injection and Stiff Knee Gait, run by Hopital Nord Franche-Comte at 1 site in France.
Trial summary
Patients who suffered a stroke, cranial traumatism, medullar lesions or multiple sclerosis can present spastic muscular complications, which is particularly impairing if it concerns muscles of the leg. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Botulinum Toxin Injection, Stiff Knee Gait, Fall Risk
- What is being tested?
- Functional clinical tests
- How many people
- 15 participants
- Where
- 1 siteFrance
- Study dates
- 1 Oct 2025to 1 Aug 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The patients consists in patients suffering from a stiff knee gait (SKG) after a stroke, a post-traumatic cerebral lesion or a multiple sclerosis, and who never underwent any neurosurgical procedure and didn't ever change their anti-spastic treatments. Those patients will be seen only in hospital structure (readaptation center) and never outside (liberal practice).
Who may be able to join
- Patient with a stif knee gait (SKG) after a stroke, a post-traumatic cerebral lesion or a multiple sclerosis.
- If the patient had a stroke, it happened at least 4 month ago (before the inclusion).
- The patient has a rectus femoris spasticity ≥ 1 on the modified Ashworth Scale with the hip in extension position.
- A quadricipital muscular force ≥ 2/5 (MRC Scale)
- The patient didn't receive any botulinum toxin injection during the 3 previous months
- No modification of any anti-spastic medication during the inclusion in the actual month (Baclofène, Dantrolène).
- No neurosurgical intervention or ligamentoplasty of the quadricipital ligament during the 6 previous months.
- No recent knee traumatism with knee instability during the 6 previous weeks.
Who cannot join
- Other comorbidities invalidating the fonctionnal tests necessary for the study like : decompensated cardiac insufficiency, unstable respiratory insufficiency, coagulation troubles, neurocognitive impairments inhibiting the comprehension of isocinetical tests.
- Patient without severe phasic trouble inhibiting the patient's ability to answer the evaluation scales.
- Sensory lesions inhibiting the possibility to evaluate the walk : visual impairment, major proprioception impairment, or cerebellar ataxia.
- Severe muscular deficit : genetic myopathy, psychomotric desadaptation syndrom
- Absolute contraindication to botulinum toxin injections : urinary tract infection ; current treatment by aminoglycosidic antibiotics, severe myasthenia, urine retention in patient who can't receive a urinary catheter.
- Patient with cognitive troubles compromitting the understanding and the realization of the study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Centre de Médecine Physique et de Réadaptation Bretegnier
Héricourt, Nord Franche-Comté, 70 400
Jean-Philippe JP Ehny, M.D, +33 84 46 57 91, JPEHNY@fondation-arcenciel.fr
Jean-Philippe JP Dr. Ehny, M.D
About this study
Official title: Analysis of Balance Disorders After Botulinum Toxin Treatment in the Rectus Femoris in Patients With a Stiff Knee Gait: What About the Risk of Falls?
Patients who suffered a stroke, cranial traumatism, medullar lesions or multiple sclerosis can present spastic muscular complications, which is particularly impairing if it concerns muscles of the leg. Muscular spastic complications of the legs can alter significantly the ability to walk because it clinically manifests itself by a stiffness of the leg, thus generating a complication called "Stif Knee Gait" (SKG). It means that the femoro-patello-tibial articulation cannot be mobilized as it should because it stays spastic instead of being mobile.
However, it remains possible to treat this kind of medical condition by using Botulinum toxin injections in the target muscle, in particular the rectus femoris (which is part of the quadriceps).
Read more
As a reminder, botulinum toxin, sold under the international common denomination "Botox®", is a neurotoxin of 150 kDa produced by the bacteria "Clostridium Botulinum" and is the most powerful natural poison known to humankind, with its DL50 between 1 and 2 nanogramms / kg in humans. This toxin works by entering the neuro-muscular synaptic junctions and by linking itself to a proteic complex called SNARE. The link between the toxin and the SNARE complex inhibits the fusion of the acetylcholinergic synaptic vesicles with the plasmic membrane of the pre-synaptic axone. The Botox® blocks the exocytosis of the acetycholin (Ach) vesicle in the inter-synaptic space at the neuro-muscular junction and blocks the nervous transmission, thus generating muscular flaccid paralysis. This kind of intoxication is caused directly by an infection by Clostridium Botulinum and is called Botulism. It manifests itself clinically by flaccid paralysis, swelling, diarrhea tiredness, respiratory failure, vomiting etc…
Despite its highly toxic properties, Botox® can be used as a therapeutic tool against number of medical conditions (strabismus, hyperhidrosis, migraines etc…) and even as a cosmetic tool (anti face-wrinkles). It can be used against spastic muscular paralysis, especially like the ones encountered in the patients of this study.
The current Standard Of Care (SOC) against SKG is to inject Botox into the rectus femoris in order to counter its spasticity. It has been shown to upgrade the walking ability of SKG patients by enhancing the leg kinetics. More precisely, it has been shown to improve the fluidity of the movement of the spastic leg in SKG patients, especially the knee flexion. However, the rectus femoris' contractility remains necessary to be able to stand up statically and to stay balanced during the walk and everyday-activity and the myorelaxant properties of Botox® may be problematic and alter the leg biomechanics despite its utility. To this day, no study has been published to compare the static and dynamic balance troubles before and after Botox injections in the rectus femoris.
The medical bibliography does not report any augmentation of the risk of fall in the case of Botox injection in the rectus femoris. However, we consider the hypothesis along which those injections can enhance the risk of fall. Therefore, we decided to conduct a monocentric, prospective observational clinical study to compare the state of the static and dynamic balance before and after Botox injections in the rectus femoris (in SKG patients) by using balance scores.
In order to complete this objective, we compared the following parameters before and after the Botox injection in SKG patients :
- Time Up and Go test(in seconds) : primary evaluation criteria
- Berg Balance Scale (BBS) : secondary evaluation criteria
- Stair climb and descent time test (SCT) : secondary evaluation criteria.
- Number of falls.
- Conditions
- Botulinum Toxin Injection, Stiff Knee Gait, Fall Risk, Rectus Femoris Muscle, Botox Injection, Spasticity With Multiple Sclerosis
- Being tested
- Functional clinical tests
- Keywords
- Botulinum toxin injection, Rectus femoris, Balance troubles, Fall risk analysis, Stiff knee gait patients.
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Functional clinical testsOther
Functional clinical tests:
- Time Up and Go test
- Berg Balance Scale (BBS)
- Stair climb and descent time test (SCT)
- Number of falls via a questionnaire
| Study group | Role | What they receive |
|---|---|---|
| Patients treated with botulinum toxin injection in the rectus femoris. | Not described Receives: Other: Functional clinical tests |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time Up and Go test.
This examination consist in 6 steps :
- Sit on a chair
- Stand up
- Walk 3 meters
- Make a U-turn
- Walk back to the chair
- Sit back.
The investigator mesures (with a chronometer) the time it takes for the patient to complete the test. The timer starts when the patient stands up, and stops when the patient sits back.
Measured: Realized only once 4 weeks after the inclusion visit.
Secondary outcomes (1)
Assessment of Berg Balance Scale test.
The Berg Balance Scale tests consists in assessing the ability of the patient to perform 14 tasks :
- 1 : to stand up of a chair without using hands
- 2 : to stand up without support
- 3 : To sit without support, feet on the floor
Measured: 4 weeks after the Botulinum toxin injection visit.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Aug 2025
- Study start1 Oct 2025 (estimated)
- Primary completion1 Aug 2026 (estimated)
- Study completion1 Aug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Botulinum Toxin InjectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 15 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hopital Nord Franche-Comte
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07108920
- Sponsor's protocol ID
- 2024-07-FEMFALLTOX
- Acronym
- FEMFALLTOX
- Status last verified
- Jul 2025
- First submitted
- 31 Jul 2025
- Last updated
- 22 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Analysis of Balance Disorders After Botulinum Toxin Treatment in the Rectus Femoris in Patients With a Stiff Knee Gait: What About the Risk of Falls?
- ClinicalTrials.gov ID
- NCT07108920
- Acronym / sponsor ID
- FEMFALLTOX / 2024-07-FEMFALLTOX
- Conditions
- Botulinum Toxin Injection, Stiff Knee Gait, Fall Risk, Rectus Femoris Muscle, Botox Injection, Spasticity With Multiple Sclerosis
- Keywords
- Botulinum toxin injection, Rectus femoris, Balance troubles, Fall risk analysis, Stiff knee gait patients.
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 15 participants (estimated)
- Lead sponsor
- Hopital Nord Franche-ComteUniversity, hospital or other
- Study start
- 1 Oct 2025 (estimated)
- Primary completion
- 1 Aug 2026 (estimated)
- Study completion
- 1 Aug 2026 (estimated)
- First posted
- 7 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients who suffered a stroke, cranial traumatism, medullar lesions or multiple sclerosis can present spastic muscular complications, which is particularly impairing if it concerns muscles of the leg. Muscular spastic complications of the legs can alter significantly the ability to walk because it clinically manifests itself by a stiffness of the leg, thus generating a complication called "Stif Knee Gait" (SKG). It means that the femoro-patello-tibial articulation cannot be mobilized as it should because it stays spastic instead of being mobile.
However, it remains possible to treat this kind of medical condition by using Botulinum toxin injections in the target muscle, in particular the rectus femoris (which is part of the quadriceps).
As a reminder, botulinum toxin, sold under the international common denomination "Botox®", is a neurotoxin of 150 kDa produced by the bacteria "Clostridium Botulinum" and is the most powerful natural poison known to humankind, with its DL50 between 1 and 2 nanogramms / kg in humans. This toxin works by entering the neuro-muscular synaptic junctions and by linking itself to a proteic complex called SNARE. The link between the toxin and the SNARE complex inhibits the fusion of the acetylcholinergic synaptic vesicles with the plasmic membrane of the pre-synaptic axone. The Botox® blocks the exocytosis of the acetycholin (Ach) vesicle in the inter-synaptic space at the neuro-muscular junction and blocks the nervous transmission, thus generating muscular flaccid paralysis. This kind of intoxication is caused directly by an infection by Clostridium Botulinum and is called Botulism. It manifests itself clinically by flaccid paralysis, swelling, diarrhea tiredness, respiratory failure, vomiting etc…
Despite its highly toxic properties, Botox® can be used as a therapeutic tool against number of medical conditions (strabismus, hyperhidrosis, migraines etc…) and even as a cosmetic tool (anti face-wrinkles). It can be used against spastic muscular paralysis, especially like the ones encountered in the patients of this study.
The current Standard Of Care (SOC) against SKG is to inject Botox into the rectus femoris in order to counter its spasticity. It has been shown to upgrade the walking ability of SKG patients by enhancing the leg kinetics. More precisely, it has been shown to improve the fluidity of the movement of the spastic leg in SKG patients, especially the knee flexion. However, the rectus femoris' contractility remains necessary to be able to stand up statically and to stay balanced during the walk and everyday-activity and the myorelaxant properties of Botox® may be problematic and alter the leg biomechanics despite its utility. To this day, no study has been published to compare the static and dynamic balance troubles before and after Botox injections in the rectus femoris.
The medical bibliography does not report any augmentation of the risk of fall in the case of Botox injection in the rectus femoris. However, we consider the hypothesis along which those injections can enhance the risk of fall. Therefore, we decided to conduct a monocentric, prospective observational clinical study to compare the state of the static and dynamic balance before and after Botox injections in the rectus femoris (in SKG patients) by using balance scores.
In order to complete this objective, we compared the following parameters before and after the Botox injection in SKG patients :
- Time Up and Go test(in seconds) : primary evaluation criteria
- Berg Balance Scale (BBS) : secondary evaluation criteria
- Stair climb and descent time test (SCT) : secondary evaluation criteria.
- Number of falls.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients treated with botulinum toxin injection in the rectus femoris. | – | Other: Functional clinical tests |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The patients consists in patients suffering from a stiff knee gait (SKG) after a stroke, a post-traumatic cerebral lesion or a multiple sclerosis, and who never underwent any neurosurgical procedure and didn't ever change their anti-spastic treatments. Those patients will be seen only in hospital structure (readaptation center) and never outside (liberal practice).
Key inclusion criteria (8 listed)
- Patient with a stif knee gait (SKG) after a stroke, a post-traumatic cerebral lesion or a multiple sclerosis.
- If the patient had a stroke, it happened at least 4 month ago (before the inclusion).
- The patient has a rectus femoris spasticity ≥ 1 on the modified Ashworth Scale with the hip in extension position.
- A quadricipital muscular force ≥ 2/5 (MRC Scale)
- The patient didn't receive any botulinum toxin injection during the 3 previous months
Key exclusion criteria (6 listed)
- Other comorbidities invalidating the fonctionnal tests necessary for the study like : decompensated cardiac insufficiency, unstable respiratory insufficiency, coagulation troubles, neurocognitive impairments inhibiting the comprehension of isocinetical tests.
- Patient without severe phasic trouble inhibiting the patient's ability to answer the evaluation scales.
- Sensory lesions inhibiting the possibility to evaluate the walk : visual impairment, major proprioception impairment, or cerebellar ataxia.
- Severe muscular deficit : genetic myopathy, psychomotric desadaptation syndrom
- Absolute contraindication to botulinum toxin injections : urinary tract infection ; current treatment by aminoglycosidic antibiotics, severe myasthenia, urine retention in patient who can't receive a urinary catheter.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Functional clinical testsFunctional clinical tests: * Time Up and Go test * Berg Balance Scale (BBS) * Stair climb and descent time test (SCT) * Number of falls via a questionnaire | Other | Patients treated with botulinum toxin injection in the rectus femoris. |
Primary outcome
Time Up and Go test.
Time frame: Realized only once 4 weeks after the inclusion visit.
This examination consist in 6 steps : 1. Sit on a chair 2. Stand up 3. Walk 3 meters 4. Make a U-turn 5. Walk back to the chair 6. Sit back. The investigator mesures (with a chronometer) the time it takes for the patient to complete the test. The timer starts when the patient stands up, and stops when the patient sits back.
1 secondary outcome
Assessment of Berg Balance Scale test.
Time frame: 4 weeks after the Botulinum toxin injection visit.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Sep 2025.
- Individual participant dataSharing planned: No
Related trials for Botulinum Toxin Injection
Recruiting
False Vocal Fold vs EMG Guided Botox for Vocal Tremor
Vocal Tremor
RecruitingPhase 2
Extracorporeal Shockwave Therapy as an Additional Treatment for Spasticity Secondary to Spinal Cord Injury
Spinal Cord Injury, Spasticity
Not yet recruiting
EMG-Guided Versus Endoscopic-Catheter Botulinum Toxin Injection for Spasmodic Dysphonia
Spasmodic Dysphonia
Not yet recruitingPhase 2
Perineural Botulinum Toxin Injection Versus Oral Duloxetine in Relief of Foot Pain in Painful Peripheral Diabetic Neuropathy
Diabetic Peripheral Neuropathy, Painful Diabetic Neuropathy
Not yet recruitingObservational study
Decision Regret Following Yonsei-Point Botulinum Toxin for Gummy Smile
Excessive Gingival Display
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Botulinum Toxin Injection and Stiff Knee Gait, run by Hopital Nord Franche-Comte at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jean-Philippe JP Ehny, M.D (+33 84 46 57 91, JPEHNY@fondation-arcenciel.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time Up and Go test. (time frame: Realized only once 4 weeks after the inclusion visit.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Sep 2025.